OcuSciences

OcuSciences is a privately-held medical device company commercializing a functional retinal imaging platform based on its patented OcuMet autofluorescence technology. The technology aims to detect oxidative stress and mitochondrial dysfunction in the eye, offering a potential tool for the early detection and monitoring of diseases like diabetic retinopathy and age-related macular degeneration. Its lead product, the OcuMet Beacon, has received FDA clearance and is positioned for commercialization in the ophthalmology diagnostics market. Founded in 2009 as a spin-out from the University of Michigan, the company is headquartered in Ann Arbor, Michigan.

OcuMet autofluorescence imaging platform for non-invasive, functional assessment of mitochondrial dysfunction and oxidative stress in the retina.

Competes against large, established players in retinal imaging (e.g., Zeiss, Heidelberg Engineering) who dominate with anatomical imaging like OCT. Differentiation is based on providing unique functional/metabolic data, not just structure. Also competes for diagnostic budget and clinical workflow mindshare within eye care practices.